Natco Pharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on Natco Pharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Natco Pharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Natco Pharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Natco Pharma Ltd (Natco Pharma) is a vertically integrated pharmaceutical company. It focuses on the development, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company also offers crop health sciences products such as Chlorantraniliprole (CTPR) insecticide. Its products are indicated for the treatment of multiple sclerosis, multiple myeloma, influenza infection, leukemia, Crohn's disease, hypertension, myelodysplastic syndrome, prostate cancer and others. The company caters its products to various industries, including healthcare and agriculture, and are used by customers in the US, Canada, Brazil, Asia-Pacific, and other countries. Natco Pharma is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
Natco House, Road No 2, Banjara Hills, Hyderabad, Telangana, 500034
Website
www.natcopharma.co.in
Telephone
91 40 23547532
No of Employees
4,199
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NATCOPHARM (NSE)
Revenue (2025)
$468.1M
-7.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-24.8%
(2025 vs 2024)
Market Cap*
$1.9B
Net Profit Margin (2025)
XYZ
-18.3%
(2025 vs 2024)
* As of and is in US$
Natco Pharma Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Finished Dosage Formulations: | Contract Manufacturing | Baricitinib |
| Oncology – Solid Tumors | Tenofovir Alafenamide Fumarate | |
| Oncology – Hematology | Natvol | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Plans/Strategy | In July, the company announced plans to invest INR2,500 crore in South Africa. |
| 2026 | New Products/Services | In March, the company introduced Pomalidomide Capsules, a generic version of Celgene’s Pomalyst in the US. |
| 2025 | New Products/Services | In October, the company launched Everolimus tablets 1mg, a generic version of Zortress by Novartis, under the therapeutic class of immunosuppressant. |
Competitor Comparison
| Key Parameters | Natco Pharma Ltd | Biocon Ltd | Divi's Laboratories Ltd | Piramal Enterprises Ltd | Jubilant Pharmova Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Hyderabad | Bengaluru | Hyderabad | Mumbai | Noida |
| State/Province | Telangana | Karnataka | Telangana | Maharashtra | Uttar Pradesh |
| No. of Employees | 4,199 | 3,442 | 18,300 | 16,397 | 978 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rajeev Nannapaneni | Chief Executive Officer; Vice Chairman | Executive Board | 2024 | 46 |
| V. C. Nannapaneni | Chairman; Managing Director | Executive Board | - | - |
| Potluri Prasad Sivaramakrishna | Executive Vice President - Corp Engineering Services; Director | Executive Board | - | - |
| Linga Rao Donthineni, Ph.D | Director; President - Technical Affairs | Executive Board | 2015 | - |
| Yaramshetty Krishna Rao | President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer